Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.18 -0.68 (-0.68%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
95 96 Next >
Nasdaq, S&P 500 Futures Pullback After Strong July; Why This Analyst Recommends Staying Fully Invested
Via Benzinga
Merck Outplays The Covid Decline, But Prometheus Buyout Weighs On Profits
Merck beat sales expectations on Tuesday, though reported losses due to its Prometheus takeover. 
Via Investor's Business Daily
Merck Announces Second-Quarter 2023 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda
Pharmaceutical company Merck & Company (NYSE: MRK) reports second quarter financial results before market open Tuesday. 
Via Benzinga
Merck & Co's Earnings Outlook
Via Benzinga
Check Out What Whales Are Doing With MRK
Via Benzinga
Earnings Extravaganza: Another One-Third Of S&P 500 Companies Report This Week, Including Amazon, Apple
(Monday market open) It’s “tech week” on Wall Street. No, wait, it’s “pharma week.” Or is it “employment week?” How about all three? 
Via Benzinga
3 Pharma Stocks to Buy for Their Promising Progress
Explore the top promising pharma stocks, leading the proverbial marathon towards transformative healthcare. 
Via InvestorPlace
7 Dow Stocks to Buy as Recession Fears Roll Back
These Dow stocks to buy are stable and look stronger as soft landing perspectives look more and more possible this year. 
Via InvestorPlace
The Dow Breaks 13-Day Winning Streak, Fed Raises Interest Rates To 2001 Levels And AI Is The Buzzword For Big Tech Earnings: The Week In The Markets
Via Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate Vaccine
Merck & Co Inc (NYSE: MRK) announced topline results from two Phase 3 trials evaluating V116, the company's investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve  
Via Benzinga
Jim Cramer Recommends Holding This Health Care Stock: 'Re-Inventing Itself, Doing A Terrific Job'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Tri Pointe Homes, Inc. (NYSE: TPH) is "still good. 
Via Benzinga
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
From Merck & Co., Inc.
Via Business Wire
Individualized Cancer Treatment: Merck/Moderna's Personalized Skin Cancer Therapy Enters Late-Stage Of Development
Merck & Co Inc (NYSE: MRK) and Moderna Inc (NASDAQ: MRNA) initiated a pivotal Phase 3 randomized V940-001 trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT),... 
Via Benzinga
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
From Merck & Co., Inc.
Via Business Wire
Moderna On Cathie Wood's Radar Ahead Of Q2 Results: Ark Boosts Stake In COVID-19 Vaccine Maker By $12M This Week
Cathie Wood's Ark Invest bought over $12 million worth of Moderna shares as the biopharma expands its pipeline beyond COVID-19. 
Via Benzinga
Merck Announces Fourth-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Russia Is Seizing European Company Assets — What US Businesses Are Still At Risk?
Via Benzinga
Analyst Cuts Nurix Therapeutics Price Target By 38%, Cites Lymphoma Data
HC Wainwright analyst Robert Burns has lowered the price target for Nurix Therapeutics Inc (NASDAQ: NRIX)  
Via Benzinga
Moderna Is Fairly Valued, Balancing Declining COVID-19 Base Business with Promising Future Pipeline: Analyst
William Blair initiated coverage on Moderna Inc (NASDAQ: MRNA) with a Market Perform rati 
Via Benzinga
Top 5 Momentum Stocks For Higher Profits In 2023
Whether you’re a seasoned investor seeking new avenues for growth or a fresh face in trading, these momentum stocks are worth considering on your journey toward financial success and capitalizing on... 
Via Talk Markets
Dow Jones Hits Milestone: 10th Straight Day In Green, Longest Winning Streak Since Early 2017
Via Benzinga
Merck Receives Positive European Union CHMP Opinion for Gefapixant
From Merck & Co., Inc.
Via Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
From Merck & Co., Inc.
Via Business Wire
Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government
Johnson & Johnson (NYSE: JNJ) has reportedly taken legal action against the U.S. 
Via Benzinga
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
Read the latest report on NanoViricides here. 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.